Cns Pharmaceuticals Inc (NASDAQ:CNSP) shares traded 7.33% higher at $0.16 on Wall Street last session.
CNSP stock price is now 9.56% away from the 50-day moving average and -98.29% away from the 200-day moving average. The market capitalization of the company currently stands at $5.24M.
On August 24, 2020, Ladenburg Thalmann recently initiated its ‘Buy’ rating on the stock quoting a target price of $11
In other news, Gumulka Jerzy, Director bought 33,333 shares of the company’s stock on Feb 01 ’24. The stock was bought for $10,000 at an average price of $0.30. Upon completion of the transaction, the Director now directly owns 43,006 shares in the company, valued at $6880.96. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 01 ’24, Director Evans Carl Anthony bought 33,333 shares of the business’s stock. A total of $10,000 was incurred on buying the stock at an average price of $0.30. This leaves the insider owning 33,458 shares of the company worth $5353.28. A total of 1.81% of the company’s stock is owned by insiders.
During the past 12 months, Cns Pharmaceuticals Inc has had a low of $0.10 and a high of $137.50. The fifty day moving average price for CNSP is $0.14316 and a two-hundred day moving average price translates $9.46681 for the stock.
The latest earnings results from Cns Pharmaceuticals Inc (NASDAQ: CNSP) was released for 2024-06-30. The company reported revenue of $2.53 million for the quarter, compared to $4.03 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -37.19 percent.
